Jiabin Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiabin Cai has a total of 289 co-authors. Here are the top co-authors by number of shared publications:
- Guo-Ming Shi
Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China
8 shared publications - Ai-Wu Ke
Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
7 shared publications Jia Fan
Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Shanghai Key Laboratory of Organ Transplantation, Zhongshan Hospital, Shanghai 200032, China
7 shared publications- Jia Fan
Fudan University
7 shared publications Chao Gao
Department of Liver Surgery and Transplantation Liver Cancer Institute Zhongshan Hospital Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion Shanghai Key Laboratory of Organ Transplantation Zhongshan Hospital Shanghai 200032 P. R. China
6 shared publicationsJian Zhou
Department of Liver Surgery and Transplantation Liver Cancer Institute Zhongshan Hospital Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion Shanghai Key Laboratory of Organ Transplantation Zhongshan Hospital Shanghai 200032 P. R. China
6 shared publications
Latest Publications
- 31 March 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (16) , 1484-1500
Dual function of DOT1L suppresses tumor cell-intrinsic immunogenicity in hepatocellular carcinoma
Immune checkpoint blockade (ICB) therapy for many cancers remains limited in patients’ overall response rate. Discovery and development of more effective combinatorial approaches is urgent. Here, through CRISPR/Cas9 genetic screens, we identify DOT1L as a versatile epigenetic factor that functions to suppress tumor-intrinsic immunity through a dual mechanism. Depletion of DOT1L induces the expression of transposable elements and subsequent type I interferon (IFN) response, and meanwhile lowers ZEB1 levels to further unleash the expression of immune-related genes. In turn, we demonstrate that DOT1L loss or treatment with the clinical stage inhibitor EPZ-5676 sensitizes tumors to ICB with increased immune infiltration in mice. More importantly, EPZ-5676 treatment alone is sufficient to enhance antitumor immunity in humanized mice. TCGA data analysis reveals an inverse correlation between DOT1L expression and IFN signatures across multiple cancer types. These findings provide a rationale for targeting DOT1L to improve tumor immunogenicity and overcome immunotherapy resistance.
- 31 March 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (16) , 1484-1500
Dual function of DOT1L suppresses tumor cell-intrinsic immunogenicity in hepatocellular carcinoma
Immune checkpoint blockade (ICB) therapy for many cancers remains limited in patients’ overall response rate. Discovery and development of more effective combinatorial approaches is urgent. Here, through CRISPR/Cas9 genetic screens, we identify DOT1L as a versatile epigenetic factor that functions to suppress tumor-intrinsic immunity through a dual mechanism. Depletion of DOT1L induces the expression of transposable elements and subsequent type I interferon (IFN) response, and meanwhile lowers ZEB1 levels to further unleash the expression of immune-related genes. In turn, we demonstrate that DOT1L loss or treatment with the clinical stage inhibitor EPZ-5676 sensitizes tumors to ICB with increased immune infiltration in mice. More importantly, EPZ-5676 treatment alone is sufficient to enhance antitumor immunity in humanized mice. TCGA data analysis reveals an inverse correlation between DOT1L expression and IFN signatures across multiple cancer types. These findings provide a rationale for targeting DOT1L to improve tumor immunogenicity and overcome immunotherapy resistance.
- Open Access
- 18 March 2026
- Published by Elsevier in Translational Oncology
- Vol. 67, 102734
Spatial remodeling of the tumor immune microenvironment in hepatocellular carcinoma with cirrhosis driven by Treg-CD8⁺T cell crosstalk via the SPP1-ITGA4 axis
- 18 March 2026
- Published by Elsevier in Translational Oncology
- Vol. 67, 102734
Open AccessSpatial remodeling of the tumor immune microenvironment in hepatocellular carcinoma with cirrhosis driven by Treg-CD8⁺T cell crosstalk via the SPP1-ITGA4 axis
- Open Access
BRD8 Disruption Unlocks Retrotransposon-Driven Tumor-Intrinsic Immunogenicity via Redistribution of Histone Acetylation in Liver Cancer
Overall response rate for immune checkpoint blockade (ICB) therapy remains limited in advanced hepatocellular carcinoma (HCC). Epigenetic perturbation has been shown to enhance tumor-intrinsic immunogenicity and thus reverse resistance to immunotherapy in multiple cancer types. Here, through domain-focused CRISPR/Cas9 genetic screens targeting chromatin regulators, we identified the bromodomain-containing protein 8 (BRD8) as a novel epigenetic factor that functions to suppress tumor-intrinsic immunity through BRD8/EP400 chromatin remodeling complex in HCC. Depletion of BRD8 potently induces anti-tumor immune responses and sensitizes tumors to ICB therapy in mouse tumor models. Mechanistically, BRD8 knockout leads to partial redistribution of H3K27ac to repetitive elements, activating double-stranded RNA (dsRNA) accumulation and subsequent type I interferon (IFN) response, leading to tumor rejection via remodeling the tumor microenvironment. The first-in-class selective chemical probe DN02 targeting the bromodomain of BRD8 also exhibits immunomodulatory and anti-tumor effects. In line with these findings, low BRD8 expression correlated with enriched interferon signatures, elevated immune cell infiltration, and prolonged survival in HCC patients. Together, this study reveals BRD8 as a selective epigenetic vulnerability for promoting tumor immunogenicity, and its bromodomain as a druggable target to overcome immunotherapy resistance in liver cancer patients. Significance: The induction of viral mimicry by epigenetic interference could trigger tumor-intrinsic immune response and enhance immunotherapy efficacy. Here, through domain-focused CRISPR/Cas9 screening, we identify BRD8 complex as a regulator involved in the suppression of repetitive elements by controlling H3K27ac distribution and propose BRD8 as a novel target to enhance anti-tumor immunity.
Open AccessBRD8 Disruption Unlocks Retrotransposon-Driven Tumor-Intrinsic Immunogenicity via Redistribution of Histone Acetylation in Liver Cancer
Overall response rate for immune checkpoint blockade (ICB) therapy remains limited in advanced hepatocellular carcinoma (HCC). Epigenetic perturbation has been shown to enhance tumor-intrinsic immunogenicity and thus reverse resistance to immunotherapy in multiple cancer types. Here, through domain-focused CRISPR/Cas9 genetic screens targeting chromatin regulators, we identified the bromodomain-containing protein 8 (BRD8) as a novel epigenetic factor that functions to suppress tumor-intrinsic immunity through BRD8/EP400 chromatin remodeling complex in HCC. Depletion of BRD8 potently induces anti-tumor immune responses and sensitizes tumors to ICB therapy in mouse tumor models. Mechanistically, BRD8 knockout leads to partial redistribution of H3K27ac to repetitive elements, activating double-stranded RNA (dsRNA) accumulation and subsequent type I interferon (IFN) response, leading to tumor rejection via remodeling the tumor microenvironment. The first-in-class selective chemical probe DN02 targeting the bromodomain of BRD8 also exhibits immunomodulatory and anti-tumor effects. In line with these findings, low BRD8 expression correlated with enriched interferon signatures, elevated immune cell infiltration, and prolonged survival in HCC patients. Together, this study reveals BRD8 as a selective epigenetic vulnerability for promoting tumor immunogenicity, and its bromodomain as a druggable target to overcome immunotherapy resistance in liver cancer patients. Significance: The induction of viral mimicry by epigenetic interference could trigger tumor-intrinsic immune response and enhance immunotherapy efficacy. Here, through domain-focused CRISPR/Cas9 screening, we identify BRD8 complex as a regulator involved in the suppression of repetitive elements by controlling H3K27ac distribution and propose BRD8 as a novel target to enhance anti-tumor immunity.
- Open Access
- 1 January 2026
- Published by China Engineering Science Press Co. Ltd. in Vita
A codon-defined translational program promotes RAS-driven cancer progression and drug resistance
Codon usage affects translation efficiency, yet how oncogenic signaling exploits codon-selective translation remains largely unknown. Here, we uncover a codon-defined translational program as a functional output of RAS-MAPK signaling. Through integrated translational analyses, we identify a codon-defined module of genes enriched for the rare arginine codon CGA, whose translation is specifically promoted by RAS activation. These genes encode key regulators of ribosome biogenesis, RNA splicing, and cell cycle control, many previously regarded as “undruggable” drivers of tumor progression and therapeutic resistance. Mechanistically, RSK (a RAS effector kinase)-mediated phosphorylation of METTL13 at S267 enhances its stability and catalytic activity toward eEF1A K55 dimethylation, accelerating CGA decoding. Disruption of this phospho-methyl relay selectively impairs CGA translation, suppresses RAS-driven tumor growth, and overcomes both intrinsic and acquired resistance to RAS pathway inhibitors. Therapeutically, combining METTL13 inhibition with RAS signaling inhibitors achieves superior tumor suppression compared with current clinical combinations of kinase inhibitors. By defining a codon-based translational mechanism, our study reveals a previously unrecognized layer of translation-level signal interpretation, introduces a “one-handle-multiple-effector” strategy to enhance the durability of targeted cancer therapies, and establishes METTL13 as a mechanistically defined and targetable node in malignant translation control.
- 1 January 2026
- Published by China Engineering Science Press Co. Ltd. in Vita
Open AccessA codon-defined translational program promotes RAS-driven cancer progression and drug resistance
Codon usage affects translation efficiency, yet how oncogenic signaling exploits codon-selective translation remains largely unknown. Here, we uncover a codon-defined translational program as a functional output of RAS-MAPK signaling. Through integrated translational analyses, we identify a codon-defined module of genes enriched for the rare arginine codon CGA, whose translation is specifically promoted by RAS activation. These genes encode key regulators of ribosome biogenesis, RNA splicing, and cell cycle control, many previously regarded as “undruggable” drivers of tumor progression and therapeutic resistance. Mechanistically, RSK (a RAS effector kinase)-mediated phosphorylation of METTL13 at S267 enhances its stability and catalytic activity toward eEF1A K55 dimethylation, accelerating CGA decoding. Disruption of this phospho-methyl relay selectively impairs CGA translation, suppresses RAS-driven tumor growth, and overcomes both intrinsic and acquired resistance to RAS pathway inhibitors. Therapeutically, combining METTL13 inhibition with RAS signaling inhibitors achieves superior tumor suppression compared with current clinical combinations of kinase inhibitors. By defining a codon-based translational mechanism, our study reveals a previously unrecognized layer of translation-level signal interpretation, introduces a “one-handle-multiple-effector” strategy to enhance the durability of targeted cancer therapies, and establishes METTL13 as a mechanistically defined and targetable node in malignant translation control.
- Open Access
- 26 December 2025
- Vol. 223 (2)
Tet2 deficiency-induced expansion of monocyte-derived macrophages promotes liver fibrosis.
Clonal hematopoiesis driven by Tet2 deficiency in myeloid cells (TetΔMye) is prevalent in elderly individuals; however, the role of Tet2ΔMye in liver fibrosis pathogenesis remains elusive. In this study, we demonstrated that Tet2-deficient monocyte-derived macrophages (MDMs) promoted cellular expansion and elevated C-C motif chemokine ligand 2/8 (Ccl2/8) secretion by stabilizing their mRNAs through 5hmC-mediated alterations in RNA-protein interactions. These chemokines engaged with the upregulated C-C motif chemokine receptor (Ccr2/3) on Tet2-/- monocytes, forming a positive feedback loop that amplified pro-inflammatory MDMs (pMDMs) accumulation in liver. Tet2-/- pMDMs activated hepatic stellate cells through IL-6, driving extracellular matrix deposition and fibrotic progression. Pharmacological inhibition of Ccl2/Ccl8 with Bindarit attenuated MDMs accumulation and liver fibrosis, whereas combined therapy with Bindarit and IL-6 neutralization synergistically suppressed liver fibrosis in Tet2ΔMye mice and aged chimeric models recapitulating Tet2ΔMye-related myeloid hematopoiesis. These findings present the mechanism that Tet2ΔMye aggravates liver fibrosis and highlight MDMs depletion plus IL-6 neutralization as a promising therapy for liver fibrosis in patients with Tet2ΔMye-related myeloid hematopoiesis.
- 26 December 2025
- Vol. 223 (2)
Open AccessTet2 deficiency-induced expansion of monocyte-derived macrophages promotes liver fibrosis.
Clonal hematopoiesis driven by Tet2 deficiency in myeloid cells (TetΔMye) is prevalent in elderly individuals; however, the role of Tet2ΔMye in liver fibrosis pathogenesis remains elusive. In this study, we demonstrated that Tet2-deficient monocyte-derived macrophages (MDMs) promoted cellular expansion and elevated C-C motif chemokine ligand 2/8 (Ccl2/8) secretion by stabilizing their mRNAs through 5hmC-mediated alterations in RNA-protein interactions. These chemokines engaged with the upregulated C-C motif chemokine receptor (Ccr2/3) on Tet2-/- monocytes, forming a positive feedback loop that amplified pro-inflammatory MDMs (pMDMs) accumulation in liver. Tet2-/- pMDMs activated hepatic stellate cells through IL-6, driving extracellular matrix deposition and fibrotic progression. Pharmacological inhibition of Ccl2/Ccl8 with Bindarit attenuated MDMs accumulation and liver fibrosis, whereas combined therapy with Bindarit and IL-6 neutralization synergistically suppressed liver fibrosis in Tet2ΔMye mice and aged chimeric models recapitulating Tet2ΔMye-related myeloid hematopoiesis. These findings present the mechanism that Tet2ΔMye aggravates liver fibrosis and highlight MDMs depletion plus IL-6 neutralization as a promising therapy for liver fibrosis in patients with Tet2ΔMye-related myeloid hematopoiesis.
- Open Access
- 2 December 2025
- Published by Elsevier in EBioMedicine
- Vol. 122, 106060
A generative vision-language model for holistic pathological assessment using preoperative imaging in hepatocellular carcinoma
- 2 December 2025
- Published by Elsevier in EBioMedicine
- Vol. 122, 106060
Open AccessA generative vision-language model for holistic pathological assessment using preoperative imaging in hepatocellular carcinoma
- 4 October 2025
- Published by Elsevier in Cell Chemical Biology
- Vol. 32 (10) , 1249-1259.e9
CBX4 acetoacetylation as an inhibitory mechanism of HIF-1α activity
- 4 October 2025
- Published by Elsevier in Cell Chemical Biology
- Vol. 32 (10) , 1249-1259.e9
CBX4 acetoacetylation as an inhibitory mechanism of HIF-1α activity
- Open Access
A multimodal LLM-agent framework for personalized clinical decision-making in hepatocellular carcinoma
- Open Access
- 2 June 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (4) , 771-788
The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC
Background and Aims: Many patients with HCC present inadequate responses to lenvatinib therapy. Therefore, it is important to elucidate the underlying mechanisms of resistance and to formulate effective reversal strategies. Approach and Results: We conducted transcriptome and proteome sequencing analyses of lenvatinib-resistant cell lines and patient-derived tissues, identifying microtubule-associated serine/threonine kinase-like (MASTL) as a critical factor associated with lenvatinib resistance in HCC. Then, we utilized subcutaneous mouse models, half maximal inhibitory concentration (IC 50 ) measurements, and colony formation assays to determine the biological function of MASTL in promoting tumor growth and mediating resistance to lenvatinib. To further elucidate the underlying mechanisms, we performed co-immunoprecipitation and mass spectrometry analyses, revealing that MASTL facilitates the phosphorylation of Y-box binding protein-1 (YBX1). Using chromatin immunoprecipitation assays, we subsequently confirmed that phosphorylated YBX1 transcriptionally activates PAK4, identifying PAK4 as a downstream effector of the MASTL pathway. Moreover, mass spectrometry and phosphorylation analysis indicated that serine/threonine protein kinase 24 (STK24), a stress-responsive kinase, can activate MASTL in HCC under lenvatinib exposure. Notably, disruption of the MASTL/YBX1/PAK4 signaling axis restored HCC sensitivity to lenvatinib. Conclusions: We propose that the MASTL/YBX1/PAK4 axis, which is activated by stress-induced STK24, plays a crucial role in lenvatinib resistance. Inhibiting this axis by targeting MASTL effectively overcomes lenvatinib resistance in HCC.
- 2 June 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (4) , 771-788
Open AccessThe MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC
Background and Aims: Many patients with HCC present inadequate responses to lenvatinib therapy. Therefore, it is important to elucidate the underlying mechanisms of resistance and to formulate effective reversal strategies. Approach and Results: We conducted transcriptome and proteome sequencing analyses of lenvatinib-resistant cell lines and patient-derived tissues, identifying microtubule-associated serine/threonine kinase-like (MASTL) as a critical factor associated with lenvatinib resistance in HCC. Then, we utilized subcutaneous mouse models, half maximal inhibitory concentration (IC 50 ) measurements, and colony formation assays to determine the biological function of MASTL in promoting tumor growth and mediating resistance to lenvatinib. To further elucidate the underlying mechanisms, we performed co-immunoprecipitation and mass spectrometry analyses, revealing that MASTL facilitates the phosphorylation of Y-box binding protein-1 (YBX1). Using chromatin immunoprecipitation assays, we subsequently confirmed that phosphorylated YBX1 transcriptionally activates PAK4, identifying PAK4 as a downstream effector of the MASTL pathway. Moreover, mass spectrometry and phosphorylation analysis indicated that serine/threonine protein kinase 24 (STK24), a stress-responsive kinase, can activate MASTL in HCC under lenvatinib exposure. Notably, disruption of the MASTL/YBX1/PAK4 signaling axis restored HCC sensitivity to lenvatinib. Conclusions: We propose that the MASTL/YBX1/PAK4 axis, which is activated by stress-induced STK24, plays a crucial role in lenvatinib resistance. Inhibiting this axis by targeting MASTL effectively overcomes lenvatinib resistance in HCC.
- Open Access
- 7 March 2025
- Published by Springer Nature in Biomarker Research
- Vol. 13 (1) , 1-20
5-Hydroxymethylcytosine modifications in circulating cell-free DNA: frontiers of cancer detection, monitoring, and prognostic evaluation
Developing accurate, clinically convenient, and non-invasive methods for early cancer detection, monitoring, and prognosis assessment is essential for improving patient survival rates, enhancing quality of life, and reducing the socioeconomic burden associated with cancer. This goal is critical in precision oncology. Genetic and epigenetic alterations in circulating cell-free DNA (cfDNA) have emerged as transformative tools for advancing early cancer detection, monitoring, and improving patient outcomes. Among these, 5-hydroxymethylcytosine (5hmC) modifications in circulating cfDNA stand out as promising epigenetic markers, offering insights into cancer initiation, progression, metastasis, and prognosis across various cancer types, such as lung cancer, colorectal cancer, and hepatocellular carcinoma. This review comprehensively explores the biology and sequencing methodologies of 5hmC, emphasizing their potential in cancer screening, diagnosis, treatment monitoring, and prognostic assessment. It highlights recent advancements in cfDNA-derived 5hmC signatures’ applications, addressing their strengths and limitations in the context of clinical translation. Furthermore, this review outlines key challenges and future directions for integrating 5hmC modifications in cfDNA into routine clinical practice, facilitating personalized and non-invasive cancer management.
- 7 March 2025
- Published by Springer Nature in Biomarker Research
- Vol. 13 (1) , 1-20
Open Access5-Hydroxymethylcytosine modifications in circulating cell-free DNA: frontiers of cancer detection, monitoring, and prognostic evaluation
Developing accurate, clinically convenient, and non-invasive methods for early cancer detection, monitoring, and prognosis assessment is essential for improving patient survival rates, enhancing quality of life, and reducing the socioeconomic burden associated with cancer. This goal is critical in precision oncology. Genetic and epigenetic alterations in circulating cell-free DNA (cfDNA) have emerged as transformative tools for advancing early cancer detection, monitoring, and improving patient outcomes. Among these, 5-hydroxymethylcytosine (5hmC) modifications in circulating cfDNA stand out as promising epigenetic markers, offering insights into cancer initiation, progression, metastasis, and prognosis across various cancer types, such as lung cancer, colorectal cancer, and hepatocellular carcinoma. This review comprehensively explores the biology and sequencing methodologies of 5hmC, emphasizing their potential in cancer screening, diagnosis, treatment monitoring, and prognostic assessment. It highlights recent advancements in cfDNA-derived 5hmC signatures’ applications, addressing their strengths and limitations in the context of clinical translation. Furthermore, this review outlines key challenges and future directions for integrating 5hmC modifications in cfDNA into routine clinical practice, facilitating personalized and non-invasive cancer management.